Why is it so hard to develop drugs for children with cancer? And what can be done about it? Those questions are central to a new study published in JAMA Oncology that explores new business models for funding drug development to treat pediatric cancers. The study, led by Andrew W. Lo, Charles E. and Susan T. Harris professor…